AMPE
AMEXAmpio Pharmaceuticals Inc.
Latest news
25 items- SECSEC Form 15-12G filed by Ampio Pharmaceuticals Inc.15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form 25 filed by Ampio Pharmaceuticals Inc.25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- PRAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is
- NEWSAmpio Pharmaceuticals Q4 EPS $(2.48) Up From $(3.60) YoYAmpio Pharmaceuticals (AMEX:AMPE) reported quarterly losses of $(2.48) per share. This is a 31.11 percent increase over losses of $(3.60) per share from the same period last year.
- SECAmpio Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- NEWSAmpio Reports Voluntary Delisting And SEC DeregistrationThe Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American.
- PRAmpio Announces Voluntary Delisting and SEC DeregistrationENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with
- SECSEC Form EFFECT filed by Ampio Pharmaceuticals Inc.EFFECT - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- NEWS12 Health Care Stocks Moving In Thursday's Intraday SessionGainers Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million. Enveric Biosciences (NASDAQ:ENVB) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million. Envoy Medical (NASDAQ:COCH) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million. Tivic Health Systems (NASDAQ:TIVC) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million. Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 e
- NEWS12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Enveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. Societal CDMO (NASDAQ:SCTL) shares moved upwards by 134.78% to $1.08. The company's market cap stands at $113.1 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 45.11% to $7.43. The company's market cap stands at $36.4 million. OneMedNet (NASDAQ:ONMD) stock moved upwards by 28.97% to $0.89. The market value of their outstanding shares is at $28.7 million. Establishment Labs Hldgs (NASDAQ:ESTA) stock increased by 21.91% to $46.89. The market value of their outstanding shares is at $1.2 billion. As per the press relea
- NEWS12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers IGC Pharma (AMEX:IGC) shares moved upwards by 14.6% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $25.4 million. Establishment Labs Hldgs (NASDAQ:ESTA) shares rose 14.43% to $44.01. The market value of their outstanding shares is at $1.1 billion. The company's, Q4 earnings came out today. Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 11.44% to $10.0. The market value of their outstanding shares is at $555.6 million. As per the press release, Q4 earnings came out today. Natera (NASDAQ:NTRA) shares moved upwards by 9.73% to $84.0. The company's market cap stands at $10.0 billion. As per the press release, Q4 earning
- NEWSAmpio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023- SEC Filing On February 26, 2024, Ampio Pharmaceuticals, Inc. (the "Company") provided a notice to H.C. Wainwright & Co., LLC to terminate that certain At The Marketing Offering Agreement, dated September 18, 2023, by and between the Company and H.C. Wainwright & Co., LLC (the "ATM Agreement"), establishing an at-the-market equity distribution program for the offer and sale from time to time shares of the Company's common stock, par value $0.0001. In accordance with the ATM Agreement, the termination will be effective March 6, 2024. In connection with the termination of the ATM Agreement, the Company filed on February 28, 2024 a post-effective amendment to its Registration Statement on Form
- SECAmpio Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form S-8 POS filed by Ampio Pharmaceuticals Inc.S-8 POS - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form S-8 POS filed by Ampio Pharmaceuticals Inc.S-8 POS - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form POS AM filed by Ampio Pharmaceuticals Inc.POS AM - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form RW filed by Ampio Pharmaceuticals Inc.RW - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECAmpio Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- NEWSAmpiolans To Take Immediate Actions To Preserve Its Cash In Order To Be Able To Adequately Fund Any Option Identified By BoardThe Company's management and the Board are currently assessing both internal and external options.
- NEWSAmpio Says Efficacy Results From Recently Completed Nonclinical Pre-IND Enabling Studies With OA-201 Do Not Support An IND Submission Which Was Anticipated In Early 2025
- PRAmpio Provides Update on Results from Pre-IND Enabling StudiesENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity. Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce p
- SECAmpio Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form 424B5 filed by Ampio Pharmaceuticals Inc.424B5 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECSEC Form 424B5 filed by Ampio Pharmaceuticals Inc.424B5 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
- SECAmpio Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
AMPE FAQ
6 questionsWhat does Ampio Pharmaceuticals Inc. do?
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is...Where does AMPE stock trade?
Ampio Pharmaceuticals Inc. (AMPE) is listed on AMEX.What sector and industry is AMPE in?
Ampio Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ampio Pharmaceuticals Inc. go public?
Ampio Pharmaceuticals Inc. (AMPE) completed its IPO in 2022.What companies are similar to AMPE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AMPE side-by-side with any of them on Quantisnow.How can I track AMPE on Quantisnow?
Quantisnow aggregates Ampio Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMPE to receive live email and push alerts on every new disclosure.